Telomir Pharmaceuticals (TELO) Competitors

$1.25 +0.02 (+1.63%)

As of 11:04 AM Eastern

TELO vs. TLSA, LFCR, ABOS, CNTN, and PLYX

Should you buy Telomir Pharmaceuticals stock or one of its competitors? MarketBeat compares Telomir Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telomir Pharmaceuticals include Tiziana Life Sciences (TLSA), Lifecore Biomedical (LFCR), Acumen Pharmaceuticals (ABOS), Hillstream Biopharma (CNTN), and Polaryx Therapeutics (PLYX). These companies are all part of the "pharmaceutical products" industry.

How does Telomir Pharmaceuticals compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Tiziana Life Sciences' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	-315.26%	-259.29%

Tiziana Life Sciences has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.33	N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 2 mentions for Telomir Pharmaceuticals. Tiziana Life Sciences' average media sentiment score of 1.89 beat Telomir Pharmaceuticals' score of 0.94 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tiziana Life Sciences beats Telomir Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

83.4% of Lifecore Biomedical shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Telomir Pharmaceuticals' return on equity of -315.26% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Telomir Pharmaceuticals	N/A	-315.26%	-259.29%

Telomir Pharmaceuticals has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.33	-$35.26M	-$0.94	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.33	N/A

In the previous week, Lifecore Biomedical had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Lifecore Biomedical and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat Lifecore Biomedical's score of 0.40 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical currently has a consensus target price of $6.00, indicating a potential upside of 31.58%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, equities analysts clearly believe Lifecore Biomedical is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifecore Biomedical beats Telomir Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Acumen Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

In the previous week, Acumen Pharmaceuticals had 8 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 10 mentions for Acumen Pharmaceuticals and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat Acumen Pharmaceuticals' score of 0.55 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals has a consensus price target of $6.67, suggesting a potential upside of 170.34%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.33	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 9.3% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals' return on equity of -121.07% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-315.26%	-259.29%
Acumen Pharmaceuticals	N/A	-121.07%	-77.77%

Telomir Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Summary

Acumen Pharmaceuticals beats Telomir Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.2% of Hillstream Biopharma shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Hillstream Biopharma had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Hillstream Biopharma and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat Hillstream Biopharma's score of 0.81 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hillstream Biopharma's return on equity of -35.59% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-35.59%	-27.05%
Telomir Pharmaceuticals	N/A	-315.26%	-259.29%

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$3.99	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.33	N/A

Hillstream Biopharma has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

Summary

Hillstream Biopharma beats Telomir Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Polaryx Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	-315.26%	-259.29%

In the previous week, Polaryx Therapeutics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Polaryx Therapeutics and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat Polaryx Therapeutics' score of 0.85 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.33	N/A

Polaryx Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 172.33%. Given Polaryx Therapeutics' higher possible upside, research analysts plainly believe Polaryx Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Polaryx Therapeutics beats Telomir Pharmaceuticals on 4 of the 5 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELO vs. The Competition

Export

Metric	Telomir Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.98M	$3.05B	$6.31B	$12.44B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-3.79	18.84	21.00	25.62
Price / Sales	N/A	287.91	558.69	75.49
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	7.35	4.35	9.84	6.72
Net Income	-$10.41M	$72.19M	$3.55B	$333.51M
7 Day Performance	-5.30%	-0.71%	-0.18%	0.32%
1 Month Performance	-4.58%	0.27%	1.54%	4.21%
1 Year Performance	-53.01%	46.27%	41.14%	36.13%

Telomir Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELO Telomir Pharmaceuticals	1.4505 of 5 stars	$1.25 +1.6%	N/A	-55.3%	$42.98M	N/A	N/A	1	Gap Up
TLSA Tiziana Life Sciences	1.032 of 5 stars	$1.47 +2.9%	N/A	-7.4%	$188.98M	N/A	N/A	8	News Coverage
LFCR Lifecore Biomedical	1.7329 of 5 stars	$5.01 -2.9%	$6.00 +19.8%	-35.3%	$188.15M	$128.87M	N/A	690	Gap Down
ABOS Acumen Pharmaceuticals	2.2314 of 5 stars	$2.60 +3.0%	$6.67 +156.9%	+137.1%	$187.44M	N/A	N/A	20	Earnings Report
CNTN Hillstream Biopharma	0.6408 of 5 stars	$3.21 -0.6%	N/A	N/A	$182.45M	N/A	N/A	2	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. TLSA, LFCR, ABOS, CNTN, and PLYX

How does Telomir Pharmaceuticals compare to Tiziana Life Sciences?

Summary

How does Telomir Pharmaceuticals compare to Lifecore Biomedical?

Summary

How does Telomir Pharmaceuticals compare to Acumen Pharmaceuticals?

Summary

How does Telomir Pharmaceuticals compare to Hillstream Biopharma?

Summary

How does Telomir Pharmaceuticals compare to Polaryx Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. TLSA, LFCR, ABOS, CNTN, and PLYX

How does Telomir Pharmaceuticals compare to Tiziana Life Sciences?

Is TLSA or TELO more profitable?

Which has more volatility & risk, TLSA or TELO?

Which has preferable valuation & earnings, TLSA or TELO?

Does the media prefer TLSA or TELO?

Do analysts recommend TLSA or TELO?

Summary

How does Telomir Pharmaceuticals compare to Lifecore Biomedical?

Do institutionals & insiders believe in LFCR or TELO?

Which has more volatility & risk, LFCR or TELO?

Is LFCR or TELO more profitable?

Which has higher valuation & earnings, LFCR or TELO?

Does the media prefer LFCR or TELO?

Do analysts prefer LFCR or TELO?

Summary

How does Telomir Pharmaceuticals compare to Acumen Pharmaceuticals?

Does the media refer more to TELO or ABOS?

Do analysts recommend TELO or ABOS?

Which has higher earnings and valuation, TELO or ABOS?

Do institutionals & insiders have more ownership in TELO or ABOS?

Is TELO or ABOS more profitable?

Which has more risk and volatility, TELO or ABOS?

Summary

How does Telomir Pharmaceuticals compare to Hillstream Biopharma?

Do analysts recommend CNTN or TELO?

Do institutionals and insiders have more ownership in CNTN or TELO?

Does the media prefer CNTN or TELO?

Is CNTN or TELO more profitable?

Which has preferable valuation and earnings, CNTN or TELO?

Which has more risk and volatility, CNTN or TELO?

Summary

How does Telomir Pharmaceuticals compare to Polaryx Therapeutics?

Is PLYX or TELO more profitable?

Does the media refer more to PLYX or TELO?

Which has better earnings & valuation, PLYX or TELO?

Do analysts prefer PLYX or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools